Overview
Clinical Meaning
Medication safety during pregnancy is governed by the interplay between fetal developmental stage, placental drug transfer, and pregnancy altered pharmacokinetics.
Medication safety during pregnancy is governed by the interplay between fetal developmental stage, placental drug transfer, and pregnancy-altered pharmacokinetics. Teratogenicity is trimester-dependent: during the pre-embryonic period (weeks 1-2, the all-or-nothing period), toxic exposures either cause embryonic death or the embryo recovers completely due to totipotent cell replacement. During organogenesis (weeks 3-8), the embryo is maximally susceptible to structural malformations because organ primordia are differentiating — each organ has a specific critical window (heart days 20-50, limbs days 24-36, palate days 47-72). During the fetal period (weeks 9-40), teratogenic exposures cause functional deficits, growth restriction, or organ-specific toxicity rather than structural malformations. Placental drug transfer follows the principles of passive diffusion: lipophilic, un-ionized, low-molecular-weight drugs (<500 Da) cross readily, while large, polar, ionized molecules cross poorly. Most medications cross the placenta, making truly safe pregnancy medications the exception rather than the rule. The 2015 FDA Pregnancy and Lactation Labeling Rule (PLLR) replaced the misleading A/B/C/D/X letter categories with narrative risk summaries under three subsections: Pregnancy, Lactation, and Females and Males of Reproductive Potential. Key pharmacological principles guide safe prescribing: acetaminophen is...